Research Roundup

Debbie Rigby rounds up the latest in research news

Pharmacologic Approaches to Glycemic Treatment of Type 2 Diabetes

This publication focuses on the full synopsis of the 2020 American Diabetes Association Diabetes Clinical Guideline relating to pharmacological treatment of type 2 diabetes. Recommendations address oral and noninsulin injectable therapies, insulin treatment, and combination injectable therapies. Results of recent large trials with cardiovascular and renal outcomes are emphasized.

Annals of internal Medicine, September 2020.

Medication-related experiences of patients with polypharmacy

A systematic review of 13 qualitative studies representing 499 patients with polypharmacy and a wide range of chronic conditions shows polypharmacy poses many challenges to patients. Polypharmacy affects patients’ lives and self-perception, and challenges with polypharmacy are not limited to practical issues of medication-taking. The authors conclude that it is crucial that healthcare professionals actively solicit individual patients’ perspectives on challenges related to polypharmacy.

BMJ Open 2020;10:e036158.

Antidepressants for smoking cessation

This Cochrane Review provides high‐certainty evidence that bupropion can aid long‐term smoking cessation. However, bupropion also increases the number of adverse events, including psychiatric AEs, and there is high‐certainty evidence that people taking bupropion are more likely to discontinue treatment compared with placebo. There is insufficient evidence to determine whether the other antidepressants tested, such as SSRIs, aid smoking cessation.

Cochrane Database of Systematic Reviews 2020, Issue 4.

Non‐steroidal anti‐inflammatory drugs for acute low back pain

This updated Cochrane Review included 32 trials to evaluate the efficacy of NSAIDs in people with acute low back pain. NSAIDs seemed slightly more effective than placebo for short‐term pain reduction (moderate certainty), disability (high certainty), and global improvement (low certainty), but the magnitude of the effects is small and probably not clinically relevant. There was no clear difference in short‐term pain reduction (low certainty) when comparing selective COX‐2 inhibitors to non‐selective NSAIDs.

Cochrane Database of Systematic Reviews 2020, Issue 4.


Previous CWH’s online sales double, thanks to COVID
Next Limited pilot to commence in late 2020

NOTICE: It can sometimes take awhile for comment submissions to go through, please be patient.

No Comment

Leave a reply